Announced details
Insilico's AI software has been used over an extended period
あすか製薬株式会社 and Insilico Medicine have launched a strategic research collaboration. あすか製薬 has used Insilico's AI software over an extended period.
Headquarters: Cambridge, Massachusetts, USA. President and CEO: Alex Zhavoronkov. A clinical-stage drug discovery and development company that uses generative AI and automation technologies. Listed on the Main Board of the Hong Kong Stock Exchange on 30 December 2025.
Insilico's Hong Kong office; headquarters of あすか製薬株式会社: Minato-ku, Tokyo
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
World Health Organization (WHO)
| Item | Details |
|---|---|
| Names of Products / Services Covered | PandaOmics, Target Identification Pro（TargetPro） |
| Counterparty | Insilico Medicine (ticker: 03696.HK) |
| Counterparty overview | Headquarters: Cambridge, Massachusetts, USA. President and CEO: Alex Zhavoronkov. A clinical-stage drug discovery and development company that uses generative AI and automation technologies. Listed on the Main Board of the Hong Kong Stock Exchange on 30 December 2025. |
| Relationship with the Company | あすか製薬株式会社 and Insilico Medicine have launched a strategic research collaboration. あすか製薬 has used Insilico's AI software over an extended period. |
| Contract Date | 24 March 2026 (announced as the start date of the strategic research collaboration) |
| Launch date | 24 March 2026 (strategic research collaboration launched; actual date) |
| Applicable area | Endometriosis, Uterine fibroids, Adenomyosis, Women's health and gynecological diseases |
| Location | Insilico's Hong Kong office; headquarters of あすか製薬株式会社: Minato-ku, Tokyo |
| Usage history | Insilico's AI software has been used over an extended period |
| Source | World Health Organization (WHO) |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To accelerate drug discovery by combining あすか製薬's expertise in gynecology with Insilico's AI-powered biological analysis capabilities for difficult-to-treat gynecological diseases, including endometriosis, uterine fibroids and adenomyosis.